Search the Community

Showing results for tags 'dvax'.

  • Search By Tags

    Type tags separated by commas.

  • Search By Author

Content Type


Forums

  • Biotech Stocks
    • General Biotech Investing Discussion
    • Daily Biotech Stock News
    • Biotech Forecast Course Discussion
  • Clinical, Regulatory and Company Catalysts
    • Event Tracker Discussion
    • Suggest Events to Add to the Event Tracker
  • BiotechForecast.com Site Updates, Announcements, & Questions
    • Site Updates & Announcements

Find results in...

Find results that contain...


Date Created

  • Start

    End

Last Updated

  • Start

    End

Filter by number of...

Joined

  • Start

    End

Group

About Me

Found 2 results

  1. Biotech_Forecast
    BERKELEY, Calif. – April 27, 2016 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the Biologics License Application (BLA) for HEPLISAV-B™, Dynavax’s investigational vaccine for immunization of adults against hepatitis B infection. In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) action date for HEPLISAV-B has been extended by three months to December 15, 2016.
  2. Biotech Forecast